OPRM1 and non-small cell lung carcinoma: LLC cells were treated with peripheral opioid antagonists, methylnaltrexone, or MOR shRNA, and an increase in MOR expression was noted in samples of patients with nonsmall cell lung cancer (NSCLC) and in several human NSCLC cell lines.